SCHEMBL2831883

SCHEMBL2831883

CCNn1c(CN2CCCC2=O)c(C(=O)O)c2cccc(F)c2c1=O

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
BDKRB1 P46663 1/20 0.42
KMT2A Q03164 2/20 0.36
HTT P42858 1/20 0.35
TSHR P16473 1/20 0.35
LMNA P02545 1/20 0.35
POLB P06746 1/20 0.34
KDM4E B2RXH2 2/20 0.33
ALDH1A1 P00352 2/20 0.33
HPGD P15428 2/20 0.33
HSD17B10 Q99714 2/20 0.33
MAPK1 P28482 1/20 0.33
CREBBP Q92793 1/20 0.33
MEN1 O00255 1/20 0.33
MAPT P10636 1/20 0.33
RECQL P46063 1/20 0.33
NQO2 P16083 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2834203 0.86 HTT (0.42) KMT2AHTTTSHRLMNAPOLB
SCHEMBL2148916 0.83 BDKRB1 (0.40) BDKRB1KMT2AHTTTSHRLMNA
SCHEMBL2830538 0.83 BDKRB1 (0.41) BDKRB1KMT2AHTTTSHRLMNA
SCHEMBL1718109 0.81 L3MBTL1 (0.40) BDKRB1KMT2AHTTTSHRPOLB
SCHEMBL13825160 0.80 BDKRB1 (0.35) BDKRB1KMT2ALMNAPOLBKDM4E
SCHEMBL2154268 0.80 CYP2C9 (0.42) BDKRB1KMT2AKDM4EMEN1NPC1
SCHEMBL2677599 0.80 MEN1 (0.40) BDKRB1KMT2ALMNAPOLBKDM4E
SCHEMBL2676781 0.78 L3MBTL1 (0.42) BDKRB1KMT2AHTTTSHRPOLB
SCHEMBL1717499 0.78 BDKRB1 (0.39) BDKRB1KMT2APOLBALDH1A1HPGD
SCHEMBL2833859 0.78 BDKRB1 (0.37) BDKRB1KMT2AHTTTSHRPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2342182-B1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS LUNDBECK & CO AS H (DK) 2012-11-14 EP claimed
US-8242134-B2 Isoquinolinone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2012-08-14 US claimed
US-20100076016-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2010-03-25 US claimed
EP-2342182-B1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS LUNDBECK & CO AS H (DK) 2012-11-14 EP disclosed
US-8242134-B2 Isoquinolinone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2012-08-14 US disclosed
US-20100076016-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2010-03-25 US disclosed
WO-2010028655-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2010-03-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100076016-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS KCNQ3, KCNK3, GRIK3 BDKRB1 421/4885KMT2A 891/4885HTT 636/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.